Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ATM they are not bearing the risk of loosing market shares since they don't do business in Canada. No one knows what could happen when it gets legalized. Maybe they could expand the Brand and offer MJ gummies in Canada. Maybe they could never make the move to go in that market. Maybe they could also loose market shares to MJ companies. Yet, no one knows.
You are seeing it as a competition instead of a helping hand.
OKAY
0.3481 ? 0.0592 (20.49%)
You already know my point.
Let's talk about objectivity...LOL
Every pinky stock does that. It offer great visibility to get new investors and finance the growth.
If someone wants to invest in a bluechip company, he should not be looking on the OTC. Theses companies are in the OTC because they cannot get a loan from an institution.
I hope people know that way before thinking of investing in the OTC...
Exactly.
The thing here is to have a long term view. We consolidated @ 0,06 $ for about 6 months before running.
Theses things take time.
It all depends on the numbers provided and the updates regarding investors concerns.
Second accountant is in top 50 Auditors since 2013 ranked by SEC registrants. Stop spreading the fear...
http://www.heincpa.com/wp-content/uploads/2014/08/Top-50-SEC-Auditor-List-2014.pdf
RCHA NEWS OUT!
BusinessWire, GlobeNewswire and PR Newswire News
Rich Pharmaceuticals Inc RCHA:OTC Pink - Current Information
Rich Pharmaceuticals' Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin's Lymphoma
GlobeNewswire
9:45 AM ET
Rich Pharmaceuticals, Inc. (OTC: RCHA), a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology, announced today the potential for using its drug RP-323 (TPA) in the treatment of Hodgkin's lymphoma.
Hodgkin's lymphoma is a cancer that is found most frequently in two different age groups: 15 - 35 and over 55. It occurs in both sexes although it is more common in males. Cancer cells invade and destroy the architecture of the lymph nodes and infiltrate the liver, the spleen or other parts of the body. In the U.S., more than 100,000 people suffer from Hodgkin's lymphoma.
"A phase I clinical trial conducted at The Cancer Institute of New Jersey have shown that RP-323 treatment reduced a palpable tumor mass after three weeks in a patient with Hodgkin's lymphoma. We look forward to being able to commence clinical trials in the future to prove that using RP-323 alone or in combination with other anticancer agents will have significant therapeutic activity against Hodgkin's lymphoma," said Rich Pharmaceuticals CEO, Ben Chang. "Clinical studies in China have also demonstrated that IV administration of RP-323 resulted in remission in some patients with myelocytic leukemia."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. is a clinical-stage Biopharmaceutical Company focused on developing innovative therapies in oncology, with initial concentration in treating Acute Myelocytic Leukemia (AML), Hodgkin's Lymphoma (HL) and other blood related diseases. It is currently in Phase 1/2 clinical trials for the treatment of AML and HL. Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. Learn more at www.richpharmaceuticals.com.
Forward-Looking Statements:
This news release contains "forward-looking state ments" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans, our financial projections or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to raise the additional funding we will need to commence clinical trials and to continue to pursue our business and product development plans, including t he business and product development plans contained in this news release, our ability to develop and commercialize products based on our technology platform, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.
Contact: Paul Knopick Pknopick@eandecommunications.com 940.262.3584 https://resource.globenewswire.com/Resource/Download/6f70b16d-5610-4c28-9575-6ad20f465dd2?size=1
They won't report them?
Last ones have been out on feb 13th, Jan 16th, Dec 19th and Nov 16th...
From the accounting firm :
When purchasing an actual company at this stage of the blockchain market it is way pricier than forming it yourself.
Therefore, you have LESS debt at the end. And why a company would buy a leading mining company when there is that much volatility? It is better to form it and grow it as the markets grows.
My opinion only.
To answer your worries on POTN update on shares,
Last time ACBFF updated their shares is 09/25/2017 and they trade on QX.
No one has the obligation to do so.
My own opinion.
what if not...
From Harbinger Reserach Report :
Never saw that method to calculate a PPS before...
Most of these companies operate at loss and have NEGATIVE CASH FLOWS.
Also, noway the pps could be 0,06$. It sat at that price for about 6-7 months before the run up.
Some here will have to chase sooooooooonnnnnnnn....
My opinion only.
Great weeks are coming! Patience will pay off!!!
Do your own DD with the information provided.
For people thinking paying researches is illegal :
It's not illegal for companies to pay promoters, as long as the compensation is disclosed and the promoter doesn't lie.
AKA any company in the OTC world.
Don't need a DD support board for that...
You forgot Vegas Show just there...
People said they didn't received any reply. He post that he received it, he has a proof, they don't.
Simple story.
$potn competitors have not as many products at less cost. Much revenues growth. Other companies are getting crushed. $potn $2.40 in line with share structure and fundamentals.
0,06$ to 0,42$ in 3 months...looks terrible.
not even 2 months....
They used current assets and current liabilities so you can do the maths...
https://www.investopedia.com/terms/a/acidtest.asp
There is even a video to explain it! :)
Still playing with the numbers to make that 450k net loss huh?!
Again, HUGE BIAS in your statements attributing the whole year expenses in RnD and prepaids to vendors to a quaterly statement...
Keep trying!
No news? we had about 3-4 news in 6-7 trading days...
News companies charge fees. It would not be moneywise to keep us updated each morning...
Taking the three last months and saying 450 000 $ loss is a HUGE BIAS since you tend to put the years expenses on these three months in your comparison.
Here : 747 453 $ for product development and testing have been added for the whole year, so if you compare with quarter statements, you sure are under.
Also : There is about a 800k$ in prepaid expenses wish they already paid for that they reported on the full year.
This is why it is important to analyse statements on the same basis.
My opinion.
1000 shares?!
1.70$ exec price. Deal!? =)
Srsly, your statements mean we should never trust a pink sheet nor pink sheet stocks never uplist to QB.
My opinion.
AUDIT WILL BE COMPLETED
I've never seen a PND over 3 months with new bases forming each week.
Real Products (many here tested), bigger revenues, profits!
I'll see you at the top guys! =)
PPS of 0.06$ valuing the company with 2016 numbers on a long period of consolidation.
Value is much much higher now with WAY BETTER NUMBERS and EXPECTED GROWTH wish must always be considered in a company valuation.
Therefore, the 0.06$ valuation is no way near a potential short-term nor long-term valuation for this company.
Debt is totally normal for a new and growing company. They obviously don't have access to the best lending since it's a new company, wish is totally normal in the Pink Sheets.
:)
Still, provinces in Canada are signing contracts with companies. Nothing to worry about!
yeah sure you really sound like serious.
Any company IN THE WORLD can pay a third party to advertise the FACTS.
Take it into your head : FACTS. THEY HAVE THE RIGHT TO DO SO!
What would be illegal would be spreading FALSE INFO.
And there is nothing here that tell uss this is FALSE INFO except the shorters.
Congratz on your 2 firsts post spamming the same thing!
We are used to ppl like u! :)
If you are that sure maybe you could buy "illegal CBD" and then sue the company for selling you illegal products and make many profits...
Otherwise I call BS, I even call BS on the fact that you are a lawyer.
:)